HUTCHMED (China) Limited (HCM) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome everyone. Thank you for joining HatchMet 2024 full year results call. Everyone is on listen only mode at this stage. We will first start off with a presentation and then we will have a Q&A at the end when you can actually enter your question in the Q&A box at the very bottom of your screen or you can also press the raise hand button where we will call your name and then you can ask the question. This information in the presentation will be also on our homepage where you can download the PowerPoint presentation as well. Should you experience any technical difficulties, please send a chat message in the chat box. This session will also be recorded and the recorded webcast will be posted on the platform in about a day or so. And just to go over some of the safe harbors statement, the performance and results of operation of HatchMet contained within this presentation are all historical in nature and past performance is no guarantee of future results. Forward-looking statements are based on current beliefs and expectation of management regarding future event and are subject to significant known and unknown risks and uncertainty. Should one of these reasons materialize, then the assumption may be proven to be incorrect and actual results may vary from what was mentioned in the forward-looking statement. Today, we will have a very good lineup of presentation. First, our Chief Executive Officer, Chief Scientific Officer, Dr. Xu, will have the opening. And then our Chief Financial Officer, Johnny Chen, will go over the 2024 financial review and outlook. And then our head of commercial, George Yuan, will go over our commercial aspects. And that will be followed by our head of R&D and chief medical officer, Michael Shi, to talk about our pipeline updates and also our ne...